 Christine Fisher
Concepts (235)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 12 | 2023 | 103 | 3.820 |
Why?
| | Uterine Cervical Neoplasms | 12 | 2023 | 216 | 3.380 |
Why?
| | Endometrial Neoplasms | 7 | 2023 | 144 | 1.880 |
Why?
| | Hysterectomy | 5 | 2019 | 117 | 1.870 |
Why?
| | Breast Neoplasms | 19 | 2023 | 1965 | 1.840 |
Why?
| | Uterine Neoplasms | 5 | 2023 | 76 | 1.760 |
Why?
| | Carcinosarcoma | 3 | 2023 | 17 | 1.520 |
Why?
| | Databases, Factual | 5 | 2021 | 1231 | 1.150 |
Why?
| | Radiation Oncology | 5 | 2022 | 76 | 1.110 |
Why?
| | Neoplasm Staging | 17 | 2021 | 1223 | 1.010 |
Why?
| | Radiosurgery | 4 | 2023 | 318 | 0.930 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 58 | 0.860 |
Why?
| | Chemoradiotherapy | 4 | 2019 | 200 | 0.850 |
Why?
| | Healthcare Disparities | 2 | 2018 | 496 | 0.820 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 5 | 2023 | 120 | 0.780 |
Why?
| | Radiotherapy, Adjuvant | 6 | 2019 | 189 | 0.770 |
Why?
| | Simulation Training | 1 | 2021 | 66 | 0.750 |
Why?
| | Margins of Excision | 1 | 2019 | 31 | 0.680 |
Why?
| | Insurance, Health | 2 | 2018 | 244 | 0.670 |
Why?
| | Aquaporin 4 | 1 | 2019 | 87 | 0.660 |
Why?
| | Necrosis | 1 | 2019 | 230 | 0.640 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1390 | 0.590 |
Why?
| | Perioperative Care | 1 | 2018 | 132 | 0.590 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 156 | 0.590 |
Why?
| | Female | 49 | 2023 | 61565 | 0.580 |
Why?
| | Insurance Coverage | 1 | 2018 | 208 | 0.570 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 31 | 0.570 |
Why?
| | Standard of Care | 1 | 2016 | 63 | 0.550 |
Why?
| | Aged | 23 | 2021 | 19657 | 0.550 |
Why?
| | Middle Aged | 27 | 2021 | 27617 | 0.540 |
Why?
| | SEER Program | 6 | 2021 | 205 | 0.530 |
Why?
| | Neoplasms | 3 | 2022 | 2179 | 0.520 |
Why?
| | Survival Rate | 7 | 2019 | 1720 | 0.510 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2021 | 900 | 0.500 |
Why?
| | Medical Errors | 1 | 2015 | 89 | 0.500 |
Why?
| | Health Plan Implementation | 1 | 2015 | 133 | 0.490 |
Why?
| | Adenocarcinoma | 3 | 2021 | 812 | 0.480 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2014 | 91 | 0.470 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1167 | 0.460 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 325 | 0.450 |
Why?
| | Carcinoma | 1 | 2014 | 204 | 0.440 |
Why?
| | Pelvis | 1 | 2013 | 92 | 0.440 |
Why?
| | Humans | 54 | 2023 | 118974 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1200 | 0.420 |
Why?
| | Combined Modality Therapy | 6 | 2020 | 1166 | 0.420 |
Why?
| | Prostatectomy | 1 | 2012 | 100 | 0.410 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 455 | 0.410 |
Why?
| | Internship and Residency | 1 | 2021 | 1001 | 0.410 |
Why?
| | Receptor, ErbB-2 | 5 | 2021 | 320 | 0.410 |
Why?
| | Carcinoma, Endometrioid | 2 | 2023 | 47 | 0.380 |
Why?
| | United States | 13 | 2022 | 12555 | 0.370 |
Why?
| | Mastectomy, Segmental | 4 | 2020 | 91 | 0.370 |
Why?
| | Adult | 19 | 2021 | 31512 | 0.360 |
Why?
| | Lymphatic Metastasis | 3 | 2021 | 307 | 0.340 |
Why?
| | Re-Irradiation | 2 | 2020 | 8 | 0.340 |
Why?
| | Cancer Pain | 2 | 2018 | 20 | 0.310 |
Why?
| | Analgesics, Opioid | 3 | 2021 | 794 | 0.300 |
Why?
| | Sarcoma | 2 | 2021 | 137 | 0.300 |
Why?
| | Prostatic Neoplasms | 2 | 2012 | 940 | 0.300 |
Why?
| | Genital Neoplasms, Female | 2 | 2018 | 72 | 0.300 |
Why?
| | Retrospective Studies | 13 | 2023 | 12978 | 0.280 |
Why?
| | Mastectomy | 3 | 2020 | 124 | 0.280 |
Why?
| | Aged, 80 and over | 10 | 2021 | 6561 | 0.280 |
Why?
| | Radiotherapy Dosage | 4 | 2023 | 245 | 0.270 |
Why?
| | Neoadjuvant Therapy | 2 | 2018 | 333 | 0.260 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2021 | 360 | 0.260 |
Why?
| | Young Adult | 8 | 2021 | 10793 | 0.260 |
Why?
| | Mutation | 2 | 2019 | 3457 | 0.260 |
Why?
| | Papillomavirus Infections | 2 | 2019 | 265 | 0.250 |
Why?
| | Medical Oncology | 4 | 2019 | 229 | 0.250 |
Why?
| | Follow-Up Studies | 4 | 2018 | 4596 | 0.240 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.240 |
Why?
| | Carcinoma, Renal Cell | 2 | 2015 | 174 | 0.230 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2023 | 14 | 0.230 |
Why?
| | Brain Neoplasms | 2 | 2023 | 1022 | 0.220 |
Why?
| | Kaplan-Meier Estimate | 4 | 2021 | 842 | 0.220 |
Why?
| | Treatment Outcome | 8 | 2023 | 9342 | 0.220 |
Why?
| | Hodgkin Disease | 2 | 2016 | 119 | 0.220 |
Why?
| | Hydrocephalus | 1 | 2023 | 81 | 0.210 |
Why?
| | Prognosis | 5 | 2018 | 3443 | 0.210 |
Why?
| | Veterans | 2 | 2022 | 1208 | 0.200 |
Why?
| | Kidney Neoplasms | 2 | 2015 | 334 | 0.200 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 35 | 0.190 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 610 | 0.180 |
Why?
| | Benzodiazepines | 1 | 2021 | 122 | 0.180 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2021 | 164 | 0.170 |
Why?
| | Lymph Nodes | 1 | 2021 | 455 | 0.170 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1440 | 0.160 |
Why?
| | Pain Management | 2 | 2018 | 294 | 0.160 |
Why?
| | Machine Learning | 1 | 2021 | 331 | 0.160 |
Why?
| | Relative Biological Effectiveness | 1 | 2017 | 3 | 0.150 |
Why?
| | Adolescent | 5 | 2019 | 18480 | 0.150 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1125 | 0.150 |
Why?
| | Vulvar Neoplasms | 1 | 2017 | 10 | 0.150 |
Why?
| | beta Catenin | 1 | 2019 | 219 | 0.150 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 67 | 0.150 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 66 | 0.140 |
Why?
| | Propensity Score | 1 | 2018 | 242 | 0.140 |
Why?
| | Breast | 1 | 2017 | 140 | 0.140 |
Why?
| | Antineoplastic Agents | 3 | 2017 | 1974 | 0.140 |
Why?
| | Logistic Models | 2 | 2018 | 1901 | 0.140 |
Why?
| | Radiotherapy Setup Errors | 1 | 2015 | 3 | 0.140 |
Why?
| | Radiation Injuries | 1 | 2017 | 131 | 0.140 |
Why?
| | Neoplasm Grading | 4 | 2019 | 258 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 93 | 0.130 |
Why?
| | Quality Control | 1 | 2015 | 159 | 0.130 |
Why?
| | Curriculum | 1 | 2021 | 910 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 794 | 0.130 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 199 | 0.130 |
Why?
| | Risk Factors | 6 | 2020 | 9000 | 0.130 |
Why?
| | Medically Uninsured | 1 | 2015 | 125 | 0.130 |
Why?
| | Checklist | 1 | 2015 | 81 | 0.130 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 93 | 0.130 |
Why?
| | Clinical Competence | 1 | 2021 | 951 | 0.130 |
Why?
| | Radiation Tolerance | 1 | 2015 | 98 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 736 | 0.120 |
Why?
| | Cancer Vaccines | 2 | 2005 | 139 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2019 | 3171 | 0.120 |
Why?
| | Breast Neoplasms, Male | 1 | 2013 | 31 | 0.120 |
Why?
| | Internet | 1 | 2018 | 633 | 0.120 |
Why?
| | Tumor Burden | 1 | 2014 | 274 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1244 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1597 | 0.110 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1129 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2015 | 199 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 462 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2017 | 523 | 0.110 |
Why?
| | Patient Safety | 1 | 2015 | 281 | 0.110 |
Why?
| | Texas | 1 | 2012 | 186 | 0.100 |
Why?
| | Medicaid | 1 | 2015 | 411 | 0.100 |
Why?
| | Peptide Fragments | 2 | 2005 | 702 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2015 | 527 | 0.100 |
Why?
| | Male | 11 | 2022 | 57801 | 0.100 |
Why?
| | Registries | 1 | 2018 | 1810 | 0.090 |
Why?
| | Disease Management | 1 | 2014 | 571 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2220 | 0.090 |
Why?
| | Age Factors | 1 | 2017 | 2995 | 0.090 |
Why?
| | Cohort Studies | 3 | 2021 | 5116 | 0.090 |
Why?
| | Quality Indicators, Health Care | 2 | 2022 | 295 | 0.090 |
Why?
| | Melanoma | 1 | 2015 | 664 | 0.090 |
Why?
| | Survival Analysis | 1 | 2012 | 1267 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2015 | 762 | 0.080 |
Why?
| | Risk Assessment | 2 | 2020 | 3057 | 0.080 |
Why?
| | Opioid-Related Disorders | 3 | 2021 | 417 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3174 | 0.080 |
Why?
| | Epidemics | 2 | 2018 | 70 | 0.070 |
Why?
| | Fertility Preservation | 2 | 2019 | 47 | 0.070 |
Why?
| | Biomarkers, Tumor | 3 | 2019 | 1059 | 0.070 |
Why?
| | Medicare | 2 | 2021 | 663 | 0.070 |
Why?
| | Prevalence | 1 | 2012 | 2326 | 0.070 |
Why?
| | Gynecology | 2 | 2018 | 184 | 0.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 143 | 0.060 |
Why?
| | Prostate-Specific Antigen | 1 | 2005 | 156 | 0.060 |
Why?
| | Radiotherapy | 2 | 2015 | 187 | 0.060 |
Why?
| | Information Seeking Behavior | 1 | 2023 | 36 | 0.060 |
Why?
| | Aromatase | 1 | 2023 | 31 | 0.060 |
Why?
| | Needles | 1 | 2023 | 56 | 0.060 |
Why?
| | Time Factors | 4 | 2020 | 6412 | 0.050 |
Why?
| | Receptors, Estrogen | 2 | 2016 | 387 | 0.050 |
Why?
| | Anthracyclines | 1 | 2021 | 41 | 0.050 |
Why?
| | Taxoids | 1 | 2021 | 98 | 0.050 |
Why?
| | Trastuzumab | 1 | 2021 | 92 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 47 | 0.050 |
Why?
| | Hospitals, University | 1 | 2021 | 172 | 0.050 |
Why?
| | Estrogens | 1 | 2023 | 328 | 0.050 |
Why?
| | Consensus | 1 | 2022 | 534 | 0.050 |
Why?
| | Quinolines | 1 | 2021 | 128 | 0.050 |
Why?
| | Radiometry | 1 | 2019 | 45 | 0.040 |
Why?
| | Prospective Studies | 3 | 2020 | 6471 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 23 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 29 | 0.040 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2019 | 42 | 0.040 |
Why?
| | Organ Sparing Treatments | 1 | 2019 | 31 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 80 | 0.040 |
Why?
| | Cervix Uteri | 1 | 2019 | 48 | 0.040 |
Why?
| | Papanicolaou Test | 1 | 2019 | 40 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2022 | 555 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 32 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 544 | 0.040 |
Why?
| | Papillomaviridae | 1 | 2019 | 101 | 0.040 |
Why?
| | India | 1 | 2018 | 141 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 262 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 143 | 0.040 |
Why?
| | Vagina | 1 | 2019 | 148 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 519 | 0.040 |
Why?
| | Organs at Risk | 1 | 2017 | 31 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1868 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 667 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 403 | 0.040 |
Why?
| | Skin Ulcer | 1 | 2015 | 15 | 0.030 |
Why?
| | Abdominal Neoplasms | 1 | 2015 | 28 | 0.030 |
Why?
| | HLA-A2 Antigen | 2 | 2005 | 39 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 34 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 703 | 0.030 |
Why?
| | Reoperation | 1 | 2017 | 557 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 483 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 278 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 128 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 996 | 0.030 |
Why?
| | Disease Progression | 2 | 2015 | 2490 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 693 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1079 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 324 | 0.030 |
Why?
| | Age Distribution | 1 | 2013 | 362 | 0.030 |
Why?
| | Sex Distribution | 1 | 2013 | 351 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1055 | 0.030 |
Why?
| | Skin | 1 | 2017 | 657 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 969 | 0.030 |
Why?
| | Comorbidity | 1 | 2017 | 1527 | 0.030 |
Why?
| | Vinblastine | 1 | 2011 | 68 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 4708 | 0.030 |
Why?
| | Mass Screening | 1 | 2019 | 1052 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 325 | 0.030 |
Why?
| | Dacarbazine | 1 | 2011 | 102 | 0.030 |
Why?
| | Remission Induction | 1 | 2011 | 247 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4196 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1293 | 0.020 |
Why?
| | Doxorubicin | 1 | 2011 | 302 | 0.020 |
Why?
| | Bleomycin | 1 | 2011 | 228 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1541 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1781 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2275 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2424 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2005 | 49 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2436 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2005 | 204 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4552 | 0.020 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2005 | 158 | 0.020 |
Why?
| | Immunoconjugates | 1 | 2005 | 89 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2005 | 509 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2005 | 736 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2005 | 702 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 2851 | 0.010 |
Why?
| | Child | 1 | 2013 | 19129 | 0.010 |
Why?
|
|
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|